PharmacoEconomics & Outcomes News 792, p7 - 2 Dec 2017
Biologics major cost driver in IBD
management in the US
The increasing use of biologic therapies for the
treatment of inflammatory bowel disease (IBD) has a
major cost impact in the US, according to researchers
from Stanford University School of Medicine, US.
The researchers used data from the Truven
Marketscan database to assess outpatient drug use
trends of IBD medications over a 9-year period
2015) and associated costs. The market share of
biologics relative to other IBD medications, including
immunomodulators, 5-aminosalicylic-acids (5-ASAs)
and oral corticosteroids, was also determined.
The analysis of data for 415 405 patients with IBD
showed that the proportion of patients using biologics
increased nearly threefold, from 7.1% in 2007 to 20.5%
in 2015. Consequently, there was a consistent rise in the
market share of biologics (from 13.7% to 30.1%) and fall
for both immunomodulators and 5-ASAs (from 22.7% to
16.0% and 48.6% to 39.2%, respectively).
Corticosteroid-only use remained stable at
approximately 15%. The per-member per-year (PMPY)
costs of an average patient receiving biologic therapy
increased from $US25 275 in 2007 to $36 051 in 2015,
and the share of PMPY costs for biologics increased from
72.9% to 85.7%. The study also showed that the share of
PMPY costs for biologics was even higher in paediatric
patients with IBD (increasing from 81.7% to 94.9%).
Yu H, et al. Market share and costs of biologic therapies for inflammatory bowel
disease in the USA. Alimentary Pharmacology and Therapeutics : 22 Nov 2017.
Available from: URL: http://doi.org/10.1111/apt.14430
PharmacoEconomics & Outcomes News 2 Dec 2017 No. 7921173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved